

Summit Adult Vaccine Recommendations Review (SAVRR) Council Meeting

May 12, 2026

Co-chairs: Dr. Bob Hopkins & Dr. Jane R. Zucker
Discussion Facilitator: L.J Tan, Co-Chair, NAIS



Agenda

- Opening statement
- ATS, CHEST, AAAAI, and SCCM to discuss their activity on respiratory viral season vaccination recommendations- Tina Hartert, American Thoracic Society Vaccine Initiative Advisory Panel
- Review draft calendar of evidence reviews and recommendation development by professional organizations- L.J Tan
- Discuss implementation of vaccination recommendations with the pharmacy associations, nursing associations, PALTmed, and senior health groups
- Discuss gaps in implementation and potential vote on a recommendation to assist providers on what to do in the fall season when timing of updated recommendations are misaligned
- June meeting- closed and open format (Closed session from 1:00 – 2:00 pm ET and open session from 2:00 – 3:00 pm ET)
- Other items from the membership
- Next meeting – June 9 from **1:00 – 3:00 pm ET**



SAVRR Council Scope and Objectives

SAVRR stands for the Summit Adult Vaccination Recommendations Review; accordingly, this group is the SAVRR Council.

Because the Summit covers influenza vaccination across the lifespan, the Council will address influenza recommendations across all ages in addition to adult vaccination recommendations.

Objective 1: Provide stakeholder feedback on recommendations

- The Council will serve as a forum—similar to the function that was previously provided by the liaisons to the ACIP—to provide stakeholder feedback to recommendation-developing bodies (currently the medical societies and professional organization who are members of SAVRR) during development and, as needed, after publication.

Objective 2: Support implementation of evidence-based recommendations

- The Council will provide guidance to support effective clinical implementation of evidence-based vaccine recommendations from professional medical societies and ACIP, as appropriate.
- This work includes identifying and clarifying differences among recommendations; highlighting gaps and opportunities for alignment; identifying interventions for the Summit's working groups and its partners; and helping to disseminate clear, practical guidance through the National Adult and Influenza Immunization Summit (NAIIS) communication channels.



Respiratory viral season vaccination recommendations
from :

American Thoracic Society (ATS)

American College of Chest Physicians (CHEST)

American Academy of Allergy, Asthma &
Immunology (AAAAI)

Society of Critical Care Medicine (SCCM)



AAAAI · ATS · CHEST · SCCM

Respiratory and Critical Care Four Society Vaccine Guidance Review Panel

May 12, 2026

Co-Chairs

Tina Hartert, MD, MPH · Justin Ortiz, MD, MS

Background

- The clinicians of the member respiratory and critical care societies care for patients across the lifespan who are at the highest risk of morbidity and mortality from vaccine-preventable diseases.
- The four founding societies of the Panel are committed to protecting patients' health and ensuring our specialty clinicians have the most reliable and clinically useful vaccine guidance to protect their patients across the lifespan, their caretakers, as well as clinicians who care for these patients.

Four Society Voting Membership and Professional Society Staff Representation

| Society | Voting Member Panel Representatives (2 per society) | Expert Contributors | Professional Society Liaison Representative |
|------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------------------|
| AAAAI American Academy of Allergy, Asthma & Immunology | Karla E. Adams, MD Amy M. Dowden, MD | | Sheila Heitzig, JD MNM CAE, Director of Practice and Policy |
| ATS American Thoracic Society | Tina Hartert, MD, MPH -- Co-Chair Justin Ortiz, MD, MS -- Co-Chair | | Karen Collishaw, CAE, Executive Director & Judy Corn, MSEd, Sr. Director, Patient Education |
| CHEST American College of Chest Physicians | Jamie Felzer, MD Kelly Pennington, MD | Ryan Maves, MD | Nicki Augustyn, CAE, Chief Strategy Officer |
| SCCM Society of Critical Care Medicine | Mark W. Hall, MD Adrienne G. Randolph, MD, MS | | Lynn Retford, CAE, Executive Director |

Draft Joint Statement

- The four founding societies of the Panel are committed to protecting patients' health and ensuring our specialty clinicians have the most reliable and clinically useful vaccine guidance to protect their patients across the lifespan, their caretakers, as well as clinicians who care for these patients.
- Since May 2025, ACIP has failed to meet standards for both scientific rigor and procedural integrity and as a result, a federal court found the reconstituted committee operated outside governing law and nullified all post-June 2025 votes.
- Based on this the four societies will not endorse current ACIP guidance on immunizations as an authoritative reference standard unless and until these standards are restored.
- **The Panel will evaluate any post-June 2025 ACIP guidance based on the quality and strength of the underlying science, independent of the ACIP's formal status, and will vote and communicate clearly to our member societies endorsement of current ACIP immunization guidance and/or the immunization guidance of other professional societies.**

Management of Conflicts of Interest

Conflicts of interest

- All Panel members declare conflicts of interest at Meeting 1 and update declarations at each subsequent meeting
- The ATS administers and maintains disclosures and develops a Panel-level management plan in consultation with the co-chairs
- All declarations were made available to all voting panel members and their society representatives. The declarations and management plan will be publicly available in derivative publications

Proposed Charter and Decision Rules

Consensus standard

- The Panel's preferred basis for all decisions is consensus, meaning no participating society objects following full deliberation
- Where consensus is not achievable, the matter will be returned for further discussion or addressed through direct consultation among the co-chairs and society liaisons

Quorum & voting

- Quorum requires at least one representative from each of the four societies; votes taken without quorum are advisory only
- Endorsement requires the affirmative agreement of all four societies
- If one or more societies decline to endorse, the remaining societies may proceed under their own names, with non-endorsing societies removed from attribution; no society will be listed as an endorser without its explicit written approval

Proposed Panel Charter and Decision Rules

Evidentiary Threshold


- Pre-June 2025 ACIP recommendations will be considered the authoritative reference standard except for those vaccines for which there is new evidence not considered by the Pre-June 2025 ACIP
 - This may include, for example, pneumococcal conjugate vaccine, clesrovimab, and meningococcal vaccines
- Burden of proof lies with any departure from Pre-June 2025 ACIP recommendations
- The Four Society Respiratory and Critical Care Societies will review and may endorse other society immunization recommendations

Discussion

- Comment
- The challenge of disparate immunization guidance across professional society guidelines
- Recommendations
- Resources
- Contact information
 - Tina Hartert, MD, MPH – tina.Hartert@vumc.org
 - Justin Ortiz, MD, MS - JOrtiz@som.umaryland.edu

Thank you

Respiratory Virus Season Calendar (July 2026 – March 2027)



Activity Update



HPV Evidence Review





The Vaccine Integrity Project's comprehensive review of peer-reviewed evidence related to human papillomavirus (HPV) vaccines finds that they **remain highly safe and effective** in preventing cervical cancer, precancerous lesions, and persistent HPV infection, with **emerging evidence supporting the potential effectiveness of a single-dose regimen** for key outcomes in women.

- [Report](#) was published online
- [Executive summary](#) posted
- [Interactive data tool](#) was launched
- Peer-reviewed publication underway

Interactive Data Tool



 **CIDRAP** Human Papillomavirus Vaccination 

Vaccine efficacy Vaccine safety **Data**

Select meta-analysis
CIN2+ with any HPV type (≥25y)

CIN2+ with any HPV type (≥ 25 years at vaccination)

| Study | Favors vaccination | Favors control | Risk ratio (95% CI) |
|------------------------|--------------------|----------------|---------------------|
| 4v Wen 2024 | | | 0.19 (0.01-4.57) |
| 2v VIVIANE 2014-INT | | | 0.95 (0.73-1.24) |
| 4v FUTURE III 2009-INT | | | 1.21 (0.84-1.75) |
| Pooled | | | 1.03 (0.83-1.28) |

Risk ratio


Select analysis type to see a forest plot summary of findings

Download the raw data, including links to source research papers



Scan to see data tool resource

High-level Draft Timeline: Fall Respiratory Immunizations



Early September: Public Rollout


- Embargoed release; background interviews
- Manuscripts go live
- Tool and summary report posted
- Medical societies post their recommendations, policy statements, etc.
- Post social media, issue press release
- Upload all final assets (e.g., toolkits, infographics, etc.) to webpages*
- Send all materials to partners
- Host webinars, media availability, etc.

*List of final deliverables under development..

Other Ongoing Activities



- **Evidence Reviews:**
 - Tdap during pregnancy initiated February 2026, product expected imminently.
 - Next review: TBD (gathering input now from the medical specialty societies)
- **Communication Efforts:** Collaboration with the Evidence Collective and Unbiased Science to address inaccurate vaccine information and improve access to evidence-based public health information.



Discussion: Implementation of vaccination recommendations

Potential Organizations:

- American Association of Nurse Practitioners (AANP)
- American College of Nurse Midwives (ACNM)
- American Geriatrics Society (AGS)
- American Nurses Association (ANA)
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)
- Gerontological Society of America (GSA)
- Post-Acute and Long-Term Care Medical Association (PALTMed)



SAVRR Council Interim Recommendation (Draft)

It is likely that 2026-27 influenza and COVID-19 updated vaccines will be released and distributed before the updated 2026-27 recommendations from relevant professional medical societies are available. The SAVRR Council recommends that healthcare professionals follow existing 2025-26 influenza, COVID, and RSV recommendations from relevant professional medical associations for administering 2026-27 vaccines, until updated recommendations for administration of 2026-27 respiratory season vaccines are available. [Where appropriate, readers should be referred to the complete source recommendations rather than reproducing all detailed clinical guidance in this document].



SAVRR Council Interim Recommendation (Draft), cont'd

Influenza

- Healthcare professionals should follow existing recommendations from the AAP, ACIP, ACOG, and AAFP until updated recommendations are released by professional medical associations. ACIP has not yet met for the upcoming season; its current recommendation remains the recommendation from the 2025 influenza season.
- Influenza vaccination is recommended for all persons 6 months of age and older [recommended by the AAP, AAFP, ACIP (2025-26 recommendations)].
- Adults 65 years of age and older should receive an enhanced influenza vaccine when available, including recombinant, adjuvanted, or high-dose influenza vaccine. If an enhanced vaccine is not available, they should receive an age-appropriate standard-dose influenza vaccine rather than defer vaccination [AAFP, ACIP (2025-26 recommendations)].
- Pregnant persons are at increased risk for complications from influenza and should receive an age-appropriate influenza vaccine [AAFP, ACOG].



SAVRR Council Interim Recommendation (Draft), cont'd

COVID-19

- Healthcare professionals should follow existing professional medical society recommendations from 2025-26 for pregnant persons (ACOG), for adults (AAFP and IDSA), and AAP recommendations for children, until updated recommendations are released. Current ACIP recommendations are from 2025, and no ACIP meetings are yet scheduled for 2026 to address influenza, COVID, or RSV.
- COVID-19 vaccination is recommended by AAFP and ACOG for all adults 19 years of age and older, including during pregnancy, with additional recommendations for immunocompromised persons from IDSA.



SAVRR Council Interim Recommendation (Draft), cont'd

RSV

- Healthcare professionals should follow existing recommendations from ACIP, ACOG, IDSA, and AAFP until updated recommendations are released by professional medical associations. ACIP has not yet met regarding recommendations for influenza, COVID, and RSV for 2026-27; its current recommendation remains the recommendation on the July 2025 ACIP adult schedule.
- RSV vaccination is recommended for all persons 75 years of age and older.
- RSV vaccination is recommended for persons 50 through 74 years of age who are at increased risk for severe RSV disease.
- RSV vaccination during pregnancy is recommended with Abrysvo® at 32 through 36 weeks' gestation, September through January in most jurisdictions, as a one-time dose. If RSV vaccine was given in a prior pregnancy, no additional maternal RSV vaccines are recommended, but infants whose birth parent was not vaccinated during the pregnancy are recommended to receive RSV monoclonal antibody.



SAVRR Council Interim Recommendation , cont'd

Potential Considerations for Influenza, COVID, or RSV Vaccination Beginning this Fall

- FDA delays in 2026-27 influenza and COVID vaccine approvals and in lot releases of these vaccines could delay vaccine availability.
- VRBPAC approved the 2026-27 influenza vaccine strain selection in March 2026. VRBPAC is expected to consider COVID-19 strain composition at its May 28, 2026, meeting; delays in VRBPAC decisions could affect the timing of fall COVID vaccine availability.
- The legal challenge to ACIP seated after April 2025 remains active. ACIP recommendations made during or after the June 2025 meeting have been stayed; therefore, current ACIP recommendations in effect by court order date to before June 2025. Additional legal developments affecting ACIP may occur.
- VIP is committed to reviewing and updating the evidence base for influenza, COVID, and RSV immunization recommendations.
- Professional medical organizations are committed to issuing updated influenza, COVID, and RSV immunization recommendations based on the latest available evidence, including the VIP evidence review. These recommendations should serve as best-practice guidance for adult and respiratory viral vaccination.
- AHIP member payors have committed to covering vaccinations through 2026; the Blue Cross Blue Shield Association has extended this commitment through 2027.



SAVRR Council Interim Recommendation (Draft) , cont'd

Potential Considerations for Influenza, COVID, or RSV Vaccination Beginning this Fall

- FDA delays in 2026-27 influenza and COVID vaccine approvals and in lot releases of these vaccines could delay vaccine availability.
- VRBPAC approved the 2026-27 influenza vaccine strain selection in March 2026. VRBPAC is expected to consider COVID-19 strain composition at its May 28, 2026, meeting; delays in VRBPAC decisions could affect the timing of fall COVID vaccine availability.
- The legal challenge to ACIP seated after April 2025 remains active. ACIP recommendations made during or after the June 2025 meeting have been stayed; therefore, current ACIP recommendations in effect by court order date to before June 2025. Additional legal developments affecting ACIP may occur.
- VIP is committed to reviewing and updating the evidence base for influenza, COVID, and RSV immunization recommendations.
- Professional medical organizations are committed to issuing updated influenza, COVID, and RSV immunization recommendations based on the latest available evidence, including the VIP evidence review. These recommendations should serve as best-practice guidance for adult and respiratory viral vaccination.
- AHIP member payors have committed to covering vaccinations through 2026; the Blue Cross Blue Shield Association has extended this commitment through 2027.

